Literature DB >> 3295763

Plasma protein binding of digitoxin and some other drugs in renal disease.

J J Lohman, F W Merkus.   

Abstract

Plasma protein binding of most acidic drugs is decreased in uraemia, whereas the binding of basic drugs is usually unchanged or decreased. Decreased protein binding in patients with renal disease mainly relates to drugs binding to albumin. Digitoxin binds to a specific site on the albumin molecule. Conflicting reports exist on digitoxin-protein binding in patients with renal disease. In ten patients with end-stage renal disease treated with haemodialysis we found only a slightly increased free fraction of digitoxin. A heparin-induced increase of the free fraction of digitoxin during haemodialysis has been reported. However, this increase was caused by the generation of non-esterified fatty acids in vitro. If this in vitro lipolysis was blocked, no increase of free digitoxin could be detected. Alterations of digitoxin-protein binding in uraemic patients during haemodialysis and during the intervals between haemodialysis treatments are small.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3295763     DOI: 10.1007/BF01960739

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  25 in total

1.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

2.  [Plasma protein binding of cardiac glycosides in limited kidney function].

Authors:  A Hawlina; K H Rahn
Journal:  Verh Dtsch Ges Inn Med       Date:  1974

3.  The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.

Authors:  D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

6.  Aromatic amino acid metabolites as potential protein binding inhibitors in human uremic plasma.

Authors:  I Tavares-Almeida; P F Gulyassy; T A Depner; E A Jarrard
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

7.  Influence of renal dysfunction on warfarin plasma protein binding.

Authors:  K Bachmann; R Shapiro; J Mackiewicz
Journal:  J Clin Pharmacol       Date:  1976-10       Impact factor: 3.126

8.  [Pharmacokinetics of digitoxin in chronic renal failure (author's transl)].

Authors:  U Peters; B Grabensee; T U Hausamen; W P Fritsch; F Grosse-Brockhoff
Journal:  Dtsch Med Wochenschr       Date:  1977-01-28       Impact factor: 0.628

9.  Correction of protein binding defect in uremic sera by charcoal treatment.

Authors:  W A Craig; M A Evenson; K P Sarver; J P Wagnild
Journal:  J Lab Clin Med       Date:  1976-04

10.  Plasma binding of disopyramide and mono-N-dealkyldisopyramide.

Authors:  J E Bredesen; E Pike; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

View more
  1 in total

1.  Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells.

Authors:  Hosam A Elbaz; Todd A Stueckle; Hua-Yu Leo Wang; George A O'Doherty; David T Lowry; Linda M Sargent; Liying Wang; Cerasela Zoica Dinu; Yon Rojanasakul
Journal:  Toxicol Appl Pharmacol       Date:  2011-10-18       Impact factor: 4.219

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.